Pamoic acid is a potent ligand for G protein Coupled Receptor 35 (GPR35) and exhibits antinociceptive property. GPR35 activation leads to increased energy utilization and the expression of anti-inflammatory genes. However, its role in brain disorders, especially in stroke, remains unexplored. Here we show in a mouse model of stroke that GPR35 activation by pamoic acid is neuroprotective. Pharmacological inhibition of GPR35 reveals that pamoic acid reduces infarcts size in a GPR35 dependent manner. The flowcytometric analysis shows the expression of GPR35 on the infiltrating monocytes/macrophages and neutrophils in the ischemic brain. Pamoic acid treatment results in a preferential increment of noninflammatory Ly-6C monocytes/macrophages in the ischemic brain along with the reduced neutrophil counts. The neuroprotective effect of GPR35 activation depends on protein kinase B (Akt) and p38 MAPK. Together we conclude that GPR35 activation by pamoic acid reprograms Ly-6C monocytes/macrophages to relay a neuroprotective signal into the ischemic brain.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287103 | PMC |
http://dx.doi.org/10.1038/s41598-020-66417-8 | DOI Listing |
Inorg Chem
July 2024
Department of Chemistry, Jadavpur University, Kolkata 700032, India.
A two-dimensional copper-based metal-organic framework, [Cu(CHO)(CHN)]·HO·DMSO, , was synthesized using pamoic acid (CHO) and 4,4'-bipyridine (CHN) as an organic ligand and Cu(II) as a metal ion. Single-crystal structure X-ray diffraction studies of the as-synthesized compound showed a two- dimensional structure with free hydroxyl groups. Upon excitation at 370 nm, the aqueous dispersion of [Cu(CHO)(CHN)]·HO·DMSO, , showed emission centered at 525 nm resulting from the intraligand energy transfer.
View Article and Find Full Text PDFJ Control Release
September 2024
Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA; Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA 23298, USA; Center for Pharmaceutical Engineering, and Institute for Structural Biology, Drug Discovery & Development (ISB3D), Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address:
The treatment landscape for opioid use disorder (OUD) faces challenges stemming from the limited efficacy of existing medications, poor adherence to prescribed regimens, and a heightened risk of fatal overdose post-treatment cessation. Therefore, there is a pressing need for innovative therapeutic strategies that enhance the effectiveness of interventions and the overall well-being of individuals with OUD. This study explored the therapeutic potential of nor-Levo-α-acetylmethadol (nor-LAAM) to treat OUD.
View Article and Find Full Text PDFSpectrochim Acta A Mol Biomol Spectrosc
October 2024
Division of Inorganic Chemistry, Department of Chemistry, Aligarh Muslim University, Aligarh 202002, India. Electronic address:
In our research we explore the world of PACDs, carbon dots synthesized from pamoic acid through a single step pyrolysis method. Our findings reveal that PACDs have capabilities of serving as sensitive and selective sensors in both colorimetric and fluorescent modes. They are particularly effective, at colorimetrically and fluorometrically detecting ferric ions and can also act as fluorometric sensors for pH.
View Article and Find Full Text PDFThe treatment landscape for opioid use disorder (OUD) faces challenges stemming from the limited efficacy of existing medications, poor adherence to prescribed regimens, and a heightened risk of fatal overdose post-treatment cessation. Therefore, there is a pressing need for innovative therapeutic strategies that enhance the effectiveness of interventions and the overall well-being of individuals with OUD. This study explored the therapeutic potential of nor-Levo-α-acetylmethadol (nor-LAAM) to treat OUD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!